Oral GLP-1s vs. injections: separating real concerns from TikTok hype

What did @philsmypharmacist actually say?

The creator's core argument is that Novo Nordisk and Eli Lilly are marketing oral GLP-1 options, specifically oral semaglutide and orforglipron, as a way to "come off your shot," but "they didn't do the studies." He says the two studies he found show that switching slows weight regain rather than preventing it, and that the companies are making inferences rather than direct claims, partly because that protects them legally. His frustration is directed at what he sees as implication-based marketing dressed up as science.

He also mispronounces orforglipron as "or for a glipton" and misattributes oral semaglutide to Lilly, when it is actually a Novo Nordisk product. Those are minor errors, but worth flagging because they suggest the claims deserve scrutiny before being taken at face value.

Does the science back this up?

Mostly, yes, with important nuance. There are no published head-to-head randomized controlled trials directly comparing outcomes when patients switch from injectable semaglutide to oral semaglutide or orforglipron for weight maintenance. That gap is real.

What we do have is data on discontinuation. The STEP 4 trial (Rubino et al., 2021, JAMA) showed that patients who stopped injectable semaglutide regained roughly two-thirds of their lost weight within a year. The OASIS 1 trial (Knop et al., 2023, The Lancet) demonstrated that oral semaglutide 50mg produces meaningful weight loss, but the population studied was not coming off injections. Orforglipron's Phase 3 ATTAIN-1 results, presented in 2024, show solid weight loss outcomes in treatment-naive patients, again not in switchers. The creator is correct that the "switch" scenario has not been formally studied.

What did they get wrong (or right)?

He got the central concern right. No published trial has specifically enrolled patients transitioning from injectable GLP-1 therapy to an oral agent and tracked long-term weight outcomes. That is a legitimate evidentiary gap, and calling it out is fair.

However, his claim that studies show "it slows the weight gain" over the long term after switching is not accurate, because those switching studies do not exist yet. He is extrapolating from discontinuation data, which is a reasonable inference, but he is presenting it as if switching studies were conducted and showed poor outcomes. That is the same inferential leap he criticizes the manufacturers for making.

He also conflates two different products from two different companies. Oral semaglutide (Rybelsus) is Novo Nordisk. Orforglipron is Eli Lilly. Bundling them together as a unified marketing conspiracy oversimplifies a more complicated regulatory and commercial picture.

What should you actually know?

If you are on injectable semaglutide or tirzepatide and a provider or advertisement suggests simply swapping to a pill to avoid injections, the honest answer is that no one has run the trial to know what happens to your weight long-term. That is not the same as knowing the switch fails, but it is also not a green light.

Oral semaglutide has substantially lower bioavailability than the injectable form, roughly 1 percent absorption under optimal fasting conditions (Buckley et al., 2018, Clinical Pharmacology and Therapeutics). The 50mg dose attempts to compensate for that, but it is not pharmacologically equivalent to the injectable. Orforglipron, as a small-molecule non-peptide GLP-1 agonist, has different absorption characteristics entirely and cannot be compared directly to semaglutide in any form.

Talk to a licensed provider before making any changes to your GLP-1 regimen. Marketing inferences are not clinical guidance.